文献速递骨质疏松与代谢性骨病

异黄酮干预对绝经后女性骨密度的影响:随机对照试验的系统综述与荟萃分析

Effects of isoflavone interventions on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials.
PubMed 文献 · Osteoporos Int · 2020-06-10

该系统综述与荟萃分析纳入63项随机对照试验、共6427名绝经后女性,评估异黄酮干预对骨密度的影响。结果显示异黄酮组在腰椎、股骨颈和桡骨远端骨密度均显著高于对照组,且干预总体安全耐受。染料木黄酮54 mg/天和依普黄酮600 mg/天是主要有效剂型,可考虑作为绝经相关骨质疏松防治的补充或替代选择。

要点

  • 异黄酮干预可显著改善绝经后女性腰椎、股骨颈和桡骨远端骨密度。
  • 染料木黄酮54 mg/天和依普黄酮600 mg/天是观察到骨密度改善的主要剂型。
  • 异黄酮干预总体安全且耐受良好,可作为绝经相关骨质疏松的补充或替代选项。

核心结论

  • 异黄酮干预,尤其是染料木黄酮54 mg/天和依普黄酮600 mg/天,对绝经后女性骨密度有改善作用且安全,可考虑作为绝经相关骨质疏松防治的补充或替代选择。

研究设计与样本

  • 系统检索PubMed、Scopus和Cochrane Library三个数据库,纳入评估异黄酮干预对绝经后女性骨密度影响的随机对照试验(RCT)。
  • 共纳入63项RCT,涉及6427名绝经后女性,采用随机效应模型计算合并效应估计。

主要发现

  • 末次随访时异黄酮组与对照组骨密度差异有统计学意义:腰椎MD=21.34 mg/cm2(95%CI=8.21至34.47 mg/cm2,p=0.001)。
  • 股骨颈MD=28.88 mg/cm2(95%CI=15.05至42.71 mg/cm2,p<0.0001)。
  • 桡骨远端MD=19.27 mg/cm2(95%CI=5.65至32.89 mg/cm2,p=0.006)。
  • 骨密度改善的正向效应主要与两种剂型相关:染料木黄酮54 mg/天和依普黄酮600 mg/天。
  • 异黄酮干预总体安全且耐受良好。

关键数值与推荐

  • 纳入标准为评估异黄酮干预对绝经后女性骨密度影响的RCT,效应量为骨密度均数差(MD)或不良结局相对风险。
  • 染料木黄酮54 mg/天和依普黄酮600 mg/天是与骨密度改善相关的主要剂型。

临床怎么用

  • 对于绝经后女性,异黄酮干预可考虑作为绝经相关骨质疏松防治的补充或替代选项。
  • 染料木黄酮54 mg/天和依普黄酮600 mg/天是文献中观察到骨密度改善的主要剂型。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Isoflavones have a structure similar to 17β-estradiol, so they may be useful to postmenopausal women in preventing bone loss related to estrogen deficiency. The present study integrated the findings from 63 randomized controlled trials and found that isoflavone interventions may have benefits in the prevention and treatment of menopause-related osteoporosis. PURPOSE: This study aimed to determine the efficacy of isoflavone interventions on bone density outcomes and the safety of isoflavone interventions in postmenopausal women by means of systematic review and meta-analysis. METHODS: A systematic search was performed on three databases (PubMed, Scopus, and Cochrane Library). Included studies were limited to randomized controlled trials (RCTs) assessing the effects of isoflavone intervention on bone mineral density (BMD) in postmenopausal women. Mean difference (MD) in BMD or relative risk for adverse outcomes was used as a summary effect measure; pooled-effect estimates were calculated using a random-effects model. RESULTS: A total of 63 RCTs, involving 6427 postmenopausal women, were included in the meta-analysis. Statistically significant differences in BMD at the last follow-up visit between the two groups (isoflavones vs. control) were found at the lumbar spine (MD = 21.34 mg/cm2, 95% CI = 8.21 to 34.47 mg/cm2, p = 0.001), the femoral neck (MD = 28.88 mg/cm2, 95% CI = 15.05 to 42.71 mg/cm2, p < 0.0001), and the distal radius (MD = 19.27 mg/cm2, 95% CI = 5.65 to 32.89 mg/cm2, p = 0.006). The positive effects in improved BMD were primarily associated with two formulations, i.e., genistein 54 mg/day and ipriflavone 600 mg/day. Isoflavone interventions were generally safe and well tolerated. CONCLUSION: Isoflavone interventions, genistein (54 mg/day) and ipriflavone (600 mg/day) in particular, have beneficial effects on BMD outcomes and are safe in postmenopausal women. They may be considered as a complementary or alternative option in the prevention and treatment of menopause-related osteoporosis.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Sansai K, Na Takuathung M, Khatsri R, et al. Effects of isoflavone interventions on bone mineral density in postmenopausal women: a systematic review and meta-analysis of randomized controlled trials. Osteoporos Int. 2020. PMID: 32524173. doi:10.1007/s00198-020-05476-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。